Anthropic's filing for a big stock offering leans hard on medicine, but no AI-designed drug has won FDA approval yet, so the promise is still unproven.
Anthropic, the company behind the Claude AI assistant, is making medicine and biology a centerpiece of its pitch to investors. Business Insider reports that the company's filing ahead of a large public stock offering next month reads like a life-sciences manifesto. After success with coding tools, Anthropic now wants to be a key player in drug research.
The filing, known as an S-1, lays out the company's goals and finances. Its second line says AI could "rapidly accelerate scientific innovation" and "bring cures for major diseases within reach." It also says nine of the 10 largest drug companies in the Fortune 500 spent at least $100,000 with Anthropic over a recent year. The same goes for eight of the 10 largest healthcare companies.
One example is Lilly. Anthropic says 50,000 Lilly employees have access to a Claude business account, and more than 85% of them actively use it. Anthropic declined to comment to Business Insider.
The company is also hiring across chemistry, experimental biology and research engineering. Two new roles offer $320,000 salaries to researchers who can design and make antibodies. Rivals are moving in too. OpenAI has an offering called Rosalind, and Google spinoff Isomorphic Labs plans to use AI to create cancer-beating drugs.
CEO Dario Amodei has long argued that biology is where AI could do the most good. He has written that he hopes AI-enabled research will help prevent and treat all infectious diseases, eliminate most cancers and double the human lifespan. He has also said he survived a cancer that would not have been treatable in the 1970s.
Not everyone shares that optimism. In an Anthropic survey from August, 91% of its staff expected AI to make a Nobel-level discovery by 2030. Only 39% of US adults agreed. And no AI-designed drug has ever received FDA approval.
If AI does speed up drug research, it could shape which treatments reach patients and what they cost. That is still a big if. The filing is a sales pitch to investors, and the results are not yet proven. Big promises about cures deserve some caution until real approved drugs show up.
Anthropic is betting big on AI-driven medicine, but with no AI-designed drug approved yet, treat the cure-all promises as hopes, not results.
A former Nvidia product manager has started Udu Technologies to let African startups and institutions rent AI computing power instead of buying it.
Read more: Ex-Nvidia engineer starts company to bring AI computing power to AfricaEA has re-released 25 classic PC games at a discount until November 19, and Bethesda has finally given The Elder Scrolls VI a subtitle: Sentinel.
Read more: EA brings 25 classic PC games back, and Elder Scrolls VI gets a nameOpenAI released a ChatGPT for analysts and bankers that shows where each number came from, a feature that could matter well beyond finance.
Read more: OpenAI launches a ChatGPT built for Wall Street analysts
